drugset
drugset / Trial / NCT00001382

A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate

NCT00001382 ↗

Phase 1 Completed 75 enrolled National Cancer Institute (NCI)
Treatment

Summary

This trial will evaluate, in patients with metastatic prostate cancer, the tolerability, toxicities, efficacy, and immunologic effects of repeated vaccinations with a recombinant vaccinia virus that contains the Prostate Specific Antigen gene (PROSTVAC).

Timeline

Start
1994-03
Primary completion
—
Completion
2000-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PROSTVAC-V Vaccine 265000 unknown Other
Subject PROSTVAC-V Vaccine 2.65e+06 unknown Other
Subject PROSTVAC-V Vaccine 2.65e+07 unknown Other
Subject PROSTVAC-V Vaccine 2.65e+08 unknown Other

Indications

prostate neoplasm